GlassScriptPhysician profile
Adam J Crane
NPI 1962062158
$6,904.03
in general payments reported to CMS, 2019-2025
13 companies · $2,863 in 2025
The $2,863 reported for 2025 was more than what 85% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2023: $166 · 2024: $3,513 · 2025: $2,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,197 · Education: $1,750 · Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,196.56 |
| Education | $1,750.00 |
| Food and Beverage | $1,596.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,955.15 | 2023-2025 | Da Vinci Surgical System |
| Becton, Dickinson and Company | $1,204.95 | 2025 | Phasix Mesh |
| Zimmer Biomet Holdings, INC. | $896.58 | 2025 | Ribfix Titan, Advantagerib |
| Davol INC. | $310.51 | 2025 | Phasix Mesh |
| Allergan, INC. | $124.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $124.47 | 2021 | |
| Atricure, INC. | $90.99 | 2021 | |
| Abbott Laboratories | $69.57 | 2023 | Perclose Proglide |
| Merck Sharp & Dohme LLC | $34.74 | 2021-2024 | Keytruda, Lynparza |
| Conmed Corporation | $33.63 | 2023 | Airseal |
| Abbvie INC. | $22.44 | 2024 | |
| Stemline Therapeutics INC. | $20.75 | 2025 | Orserdu |
| Phathom Pharmaceuticals, INC. | $15.28 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.